Letter of Intent dated February 4, 2019 among the registrant, Novo Healthnet Limited and Pulse Rx Inc

EX-10.2 3 ex10-2.htm


Exhibit 10.2


Novo Integrated Sciences Inc./ Novo Healthnet Limited

11120 NE 2nd Street, Suite 200

Bellevue, Washington 98004


February 4, 2019


Pulse Rx LTC Pharmacy

111 Zenway Blvd., Suite #3

Woodbridge, Ontario

Canada, L4H 3H9


Attention: Martin Kusmirek


Re: Letter of Intent for the Acquisition by Novo Healthnet Limited of 100% of the issued and outstanding equity stock of Pulse Rx Inc.


This binding letter of intent (“LOI” or “Letter”), is to generally record terms and conditions of the proposed agreement whereby Novo Integrated Sciences Inc., a Nevada corporation (“NVOS”) and Novo Healthnet Limited, a wholly owned Canadian subsidiary of NVOS (“NHL”) will acquire all of the issued and outstanding shares of Pulse Rx Inc. (“Pulse”), a limited company incorporated under the laws of Ontario, operating as Pulse Rx LTC Pharmacy, (the “Transaction”). This Letter represents only our good-faith intention to negotiate and enter into a definitive agreement in a form acceptable to NVOS and Pulse.


This Letter is a binding agreement between us. Notwithstanding the foregoing, the parties acknowledge and confirm it is their intention that this Letter will serve only as a preliminary interim agreement in relation to the matters described herein, which will apply until the Definitive Agreement (as defined below) is concluded.


Statements below as to what we, or you, will do, or agree to do, or the like, are so expressed for convenience only, and are understood in all instances (except for the items identified below in Section 11) to be subject to our mutual continued willingness to proceed with the Transaction.


The following paragraphs reflect our preliminary agreement with respect to the Transaction (as defined below):


1. Structure: The parties intend to enter into a share exchange or other similar business combination in which:


(i) NVOS will issue, based on a valuation of Pulse purchase price of $6 million CAD, the equivalent in capital stock based on the 30-trading day average share price in exchange for the shares of NHL issued pursuant to the Transaction. The issued shares will be subject to a two-year lock up coinciding with the claw-back identified in Item 1.viii of this Agreement. In the event the claw-back is waived prior to the two-year claw-back term, the lock-up will be removed and normal rule 144 restrictions will apply.


(ii) For the sake of clarity; the current shareholder structure is referenced in our filings.


(iii) Upon completion of the Transaction, Pulse shall have been advanced a loan in an amount not to exceed $6 million CAD, with the use and disbursement of funds to be itemized pursuant to the definitive agreement and NVOS will hold all the issued and outstanding shares of Pulse and Pulse shall be the wholly-owned subsidiary of NVOS or NHL, as determined in the definitive agreement.




(iv) Pulse will have the right to appoint a board member to the board of directors of NVOS.


(v) Performance bonuses related to proprietary SOPs and other Pulse intellectual property will be identifiable in a definitive agreement.


(vi) The undersigned principal of Pulse shall enter into an employment agreement for a period of no less than two years from the close of the Transaction. The employment agreement will identify specific bonus structures related to subsidiary revenue performance as well as total corporate performance.


(vii) The vendor(s) has the right to exercise a ‘claw-back’ within a two-year period commencing the date of the closing of this transaction. The claw-back will result in the mutual return of Pulse and NVOS shares, which shares were the subject of a share exchange, to the respective parties should targets not be met by NVOS as identified in a definitive agreement.


2. Due Diligence: The parties will work promptly to carry out all required due diligence in respect of the proposed Transaction including without limitation, the completion of standard business, legal and other inquiries and a review of applicable laws and regulations. The parties will afford each other, its employees, auditors, legal counsel, and other authorized representatives all reasonable opportunity and access during normal business hours to inspect and investigate the business and financial affairs of the other party.


3. Definitive Agreement. We mutually agree to proceed reasonably and in good faith toward the negotiation and execution of definitive documentation which shall contain the terms and conditions set out in the LOI and such other terms, conditions, indemnities, representations, warranties, covenants as are customary for transactions of this nature (the “Definitive Agreement”). The parties shall cooperate in structuring the Transaction in the most effective manner having regard to applicable tax, corporate, and securities laws. Upon the execution and delivery of the Definitive Agreement, it will supersede this Letter.


4. Regulatory Approvals and Contractual Consents: Each of the parties will use its commercially reasonable best efforts to obtain:


(i). the necessary board approvals and shareholder approvals for the Transaction prior to the execution of the Definitive Agreement; and


(ii). all necessary regulatory approvals (including approvals from any licensing authorities) and third-party consents and the necessary shareholder approvals prior to the closing of the Transaction and to cooperate in providing any submissions necessary to affect the Transaction.


5. Other Conditions. The Definitive Agreement shall include, but will not be limited to, the following:


(i). the parties having completed a due diligence investigation the results of which are satisfactory to the parties their sole discretion;


(ii). at the time of the Transaction, Pulse will have no liabilities, contingent or otherwise, unless such liabilities have been specifically agreed to by NVOS in writing;


(iii). Pulse will not be debarred or lose its status with any third-party or government payor/services for the provision of pharmacy services because of the Transaction;


(iv). Pulse will have received all regulatory approvals required to complete the Transaction;




(v). the parties agree to cooperate to prepare for filing the necessary current reports with the Securities and Exchange Commission with respect to the Transaction, including a Form 8-K, within the regulatory required time limits following the closing of the Transaction


(vi). the representations and warranties contained herein shall be true and correct in all material respects as of the closing of the Transaction; and


(vii). no material adverse change shall have occurred in the business, assets, liabilities, results, financial condition, affairs or prospects of Pulse from the date hereof to the closing of the Transaction.


6. Adjustment of Officers and Directors: At the closing of the Transaction, Pulse will appoint a director to each of the NHL and the NVOS boards as described above.


7. Confidentiality: Each party agrees that, subject to compliance with applicable laws, it will keep confidential, and not release to any other person, this proposal, the contents of this non-binding Letter of Intent and any of the proprietary business, technical or other information obtained by it during its due diligence inquiries and any related negotiations. Each party’s obligations in this respect shall survive the closing of the Transaction or any termination of the proposed Transaction between the parties or the termination of this LOI.


8. Disclosure: No public announcement concerning the Transaction contemplated herein or the status of the discussions between the parties hereto shall be made by either party unless and until the same has been approved by both parties hereto, unless such disclosure is required by any government laws, rules or regulations, by any government regulatory authorities or any stock exchange having jurisdiction over either party provided prior written notice is provided to the other party respecting such disclosure or public announcement and such party has been provided reasonable opportunity to review and comment on the proposed disclosure.


9. Costs: The parties will each be solely responsible for and bear their own respective expenses, including, without limitation, expenses of legal counsel, accountants, and other advisors, incurred at any time in connection with pursuing or consummating the Transaction. Each party’s obligations in this respect shall survive the closing of the Transaction or any termination of the proposed Transaction between the parties. It is expressly understood that both parties’ counsel will be together, responsible for preparing the documents required to complete the Transaction including the filing statement required to be filed with the Exchange in connection with the Transaction.


10. Exclusivity: The parties hereby agree that until the Termination Date (as defined below) and the date the parties enter into the Definitive Agreement, that neither party, their respective directors, officers, agents and representatives will not, directly or indirectly:


(i) solicit, initiate or encourage the initiation of any expression of interest, inquiries or proposals regarding, constituting or that may reasonably be expected to lead to any merger, amalgamation, take-over bid, tender offer, arrangement, recapitalization, liquidations, dissolution, share exchange, sale of material assets involving the parties or a proposal or offer to do so (the “Acquisition Proposal”) (including without limitation, any grant of an option or other right to take any such action);


(ii). participate in any discussions or negotiations regarding an Acquisition Proposal;


(iii). accept or enter into, or propose publicly to accept or enter into, any agreement, letter of intent, memorandum of understanding or any arrangement in respect of an Acquisition Proposal; and


(iv) otherwise cooperate in any way, assist or participate in, facilitate or encourage any effort or attempt by any person to do any of the foregoing.




11. Binding Effect: The consummation of the Transaction is subject to the entry of the Definitive Agreement. The Definitive Agreement is subject to the board approval of each of the parties.


12. Termination: If the Definitive Agreement is not negotiated and executed by both parties on or before February 12th, 2019 or such other date as agreed to by the parties, (the “Termination Date”) the terms of this LOI will be of no further force or effect except for Section 7 (Confidentiality), Section 9 (Costs) and Section 13 (Governing Laws). Section 7 and Section 13 will remain in effect for a period of one (1) year following the date this LOI is terminated.


13. Governing Laws: This Letter of Intent will be governed by and be construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein. The parties agree that any dispute arising out of or relating to this LOI shall be subject to the exclusive jurisdiction of the courts in and for the Province of Ontario and each party agrees to submit to the personal and exclusive jurisdiction and venue of such courts. Governing law and jurisdiction regarding the Definitive Agreement shall be negotiated between and agreed to by the parties and set out in the Definitive Agreement.


If the terms outlined above are acceptable to you please sign and date this Letter in the space provided below and return a signed copy to the undersigned.


  Very truly yours,
  By: /s/ Robert Mattacchione
    Robert Mattacchione
    Novo Integrated Sciences, CEO
    Novo Healthnet Limited, Chairman
  ACKNOWLEDGED AND AGREED to on: February 4, 2019
  By: /s/ Martin Kusmirek
    Martin S. Kusmirek, President
    Pulse Rx Inc. o/a Pulse Rx LTC Pharmacy